Skip to main content

Table 6 Comparison between VS and non-VS groups of RA stage III or IV patients (univariate analysis)

From: Risk factors associated with cervical spine lesions in patients with rheumatoid arthritis: an observational study

  VS group (n = 30) Non-VS group (n = 99) P-value*
Sex (n) (male:female) 4:26 2:97 0.04
Age (years) (IQR) 68 (64−72) 68 (61−73) 0.65
Age of onset (years) (IQR) 48 (39−56) 50 (40−60) 0.17
RA duration (years) (IQR) 18 (13−26) 14 (6−26) 0.10
CRP level (mg/dL) (IQR) 0.7 (0.4−1.6) 0.3 (0.1−0.8) < 0.01
RF positive (n) 57 % (17/30) 69 % (68/99) 0.22
MMP3 (n) 63 % (19/30) 68 % (67/99) 0.66
DAS28-CRP (IQR) 2.9 (2.2−3.6) 2.1 (1.7−2.8) 0.06
Prednisolone (n) 70 % (21/30) 46 % (46/99) 0.02
MTX (n) 53 % (16/30) 66 % (65/99) 0.22
Biological agents (n) 43 % (13/30) 31 % (31/99) 0.22
BMD of the lumbar spine (IQR) 79 (74−91) 81 (70−91) 0.95
BMD of the femoral neck (IQR) 60 (49−67) 66 (59−74) 0.02
Previous joint surgery (n) 67 % (20/30) 30 % (30/99) < 0.01
  1. BMD bone mineral density, DAS28-CRP Disease Activity Score based on C-reactive protein, MTX methotrexate, RA rheumatoid arthritis, VS vertical subluxation, RA rheumatoid arthritis, IQR interquartile range
  2. *The P-value was calculated using the Fisher exact test, Mann-Whitney U test, Student t-test, or chi-square test